Patent intelligence · US
US 12180471
Antisense oligonucleotides for the treatment of Stargardt disease
Antisense oligonucleotides for the treatment of Stargardt disease
Patent details — US 12180471
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 31, 2024
- Expiration
- Dec 26, 2044
- Applicant
- ProQR Therapeutics II B.V.
- Claims
- 5
- CPC classes
- A61K, A61K31/713, A61P, A61P27/02
Quick answer
US 12180471 (Antisense oligonucleotides for the treatment of Stargardt disease) is held by ProQR Therapeutics II B.V.. Status: granted. Granted Dec 31, 2024. Expires Dec 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ProQR Therapeutics II B.V.
- Grant date
- Expiration
- Claims
- 5
- CPC classes
- A61K, A61K31/713, A61P, A61P27/02
More from ProQR Therapeutics II B.V.
Related pharmaceutical patents in our USPTO index.
-
US 12275937
Stereospecific linkages in RNA editing oligonucleotides
granted -
US 12203072
Chemically modified single-stranded rna-editing oligonucleotides
granted -
US 12018257
Single-stranded RNA-editing oligonucleotides
granted -
US 11920132
Oligonucleotide therapy for Leber congenital amaurosis
granted -
US 11851656
Chemically modified single-stranded RNA-editing oligonucleotides
granted -
US 11649454
Single-stranded RNA-editing oligonucleotides
granted -
US 11479771
Antisense oligonucleotides for the treatment of eye disease
granted
Frequently asked questions
What is US patent 12180471?
US 12180471 (Antisense oligonucleotides for the treatment of Stargardt disease) is held by ProQR Therapeutics II B.V.. Status: granted. Granted Dec 31, 2024. Expires Dec 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12180471?
ProQR Therapeutics II B.V. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 19 pharmaceutical patents for this assignee.
When does US 12180471 expire?
Our index shows an expiration date of Dec 26, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.